XML 51 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] Restructuring
2020 Restructuring Program
During 2020, Viatris announced a significant global restructuring program in order to achieve synergies and ensure that the organization was optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. As part of the restructuring, the Company optimized its commercial capabilities and enabling functions, and closed, downsized or divested certain manufacturing facilities globally that were deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products. The actions under the 2020 restructuring program were substantially completed during 2023.
Since the initiation of the 2020 restructuring program, the Company has incurred total pre-tax charges of approximately $1.4 billion through December 31, 2023. Such charges included approximately $450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs, and cash costs of approximately $950 million, primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations and other plant disposal costs.
The following table summarizes the restructuring charges and the reserve activity for the restructuring program:
(In millions)Employee Related CostsOther Exit CostsTotal
Balance at December 31, 2020$262.6 $4.8 $267.4 
Charges (3)
396.1 496.1 892.2 
Reimbursable restructuring charges26.4 — 26.4 
Cash payment(385.5)(151.7)(537.2)
Utilization— (345.0)(345.0)
Foreign currency translation(7.0)(0.1)(7.1)
Balance at December 31, 2021$292.6 $4.1 $296.7 
Charges (2)
38.2 48.3 86.5 
Cash payment(170.1)(15.3)(185.4)
Utilization— (34.9)(34.9)
Foreign currency translation(5.1)(0.3)(5.4)
Balance at December 31, 2022$155.6 $1.9 $157.5 
Charges (1)
17.6 107.6 125.2 
Cash payment(77.8)(10.3)(88.1)
Utilization (4)
(4.0)(99.2)(103.2)
Foreign currency translation0.8 — 0.8 
Balance at December 31, 2023$92.2 $— $92.2 
____________
(1)     For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $80.3 million, $0.4 million, $29.5 million, $13.9 million, and $1.1 million, respectively.
(2)     For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $74.6 million, $2.5 million, $0.9 million, $8.2 million, and $0.3 million, respectively.
(3)     For the year ended December 31, 2021, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, and $94.1 million and $30.4 million, respectively.
(4)     For the year ended December 31, 2023, other exit costs included expense of $71.6 million relating to plant divestitures.
At December 31, 2023 and 2022, accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities and other long-term obligations in the consolidated balance sheets.